Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40BBS | ISIN: US2498454055 | Ticker-Symbol:
NASDAQ
24.04.25
19:30 Uhr
0,770 US-Dollar
-0,031
-3,92 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DERMATA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DERMATA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur DERMATA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DERMATA THERAPEUTICS Aktie jetzt für 0€ handeln
15.04.Dermata Therapeutics files to sell 10.01M shares of common stock for holders1
15.04.Dermata meldet frühen Erfolg bei Aknebehandlung mit XYNGARI3
15.04.Dermata reports early success in acne treatment with XYNGARI2
15.04.Dermata Therapeutics: Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks196- Dermata previously announced XYNGARI produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -- Additional data analysis revealed that XYNGARI...
► Artikel lesen
15.04.Dermata Therapeutics, Inc. - 8-K, Current Report2
28.03.Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules392SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of...
► Artikel lesen
27.03.Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne2
27.03.Dermata Therapeutics, Inc.: BREAKING: Dermata's XYNGARI Phase 3 Trial Topline Data Meets All Primary Endpoints164- XYNGARI achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARI is the first once-weekly...
► Artikel lesen
27.03.Dermata shares rise on positive acne treatment trial results1
25.03.Dermata Therapeutics, Inc. - 8-K, Current Report3
17.03.Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results246- Dermata expects to announce topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 -- The Company recently entered into a Clinical...
► Artikel lesen
17.03.Dermata Therapeutics, Inc. - 8-K, Current Report2
17.03.Dermata Therapeutics, Inc. - 10-K, Annual Report4
04.03.Dermata Therapeutics, Inc.: Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI Phase 3 STAR-1 Clinical Trial for Acne96- STAR-1 topline results expected by the end of March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year - - XYNGARI Phase 3 STAR-1 trial...
► Artikel lesen
25.02.Dermata Therapeutics: Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis571- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Company recently entered into a Clinical Trial...
► Artikel lesen
29.01.Dermata Therapeutics: Dermata to Present on BioPub on January 31, 2025263- Dermata's Chief Executive Officer and Chief Development Officer will provide a corporate update and answer live questions from the biotech investment community -SAN DIEGO, CA / ACCESS Newswire / January...
► Artikel lesen
28.01.Dermata Therapeutics: Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment305- This is Dermata's first issued U.S. patent for XYNGARI, which uses its Spongilla technology to topically treat acne -- Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI clinical...
► Artikel lesen
23.01.Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules410SAN DIEGO, CA / ACCESS Newswire / January 23, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment...
► Artikel lesen
22.01.Dermata Therapeutics announces $2.55M private offering2
22.01.Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules321SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment...
► Artikel lesen
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1